PURPOSE: To describe an interesting case with a typical chloroquine bull's eye maculopathy with important results of the electrophysiological tests and verify if any reduction of focal responses, detected in multifocal electroretinogram (mfERG), are congruent with any possible defects detected in the visual field. CASE REPORT: A 59-year-old man took a daily dosage of 250 mg chloroquine for his rheumatoid arthritis (up to a total dose of 540 g). He had the typical chloroquine-induced bull's-eye maculopathy. The electro-oculogram was normal. The mfERG, demonstrated reduced focal responses in the areas corresponding to the scotoma detected in the visual field. CONCLUSIONS: Considering the normality of the electro-oculogram, we can easily conclude that the electro-oculogram is not sensible to detect chloroquine maculopathy and that reported reductions may occur due to the course of the rheumatoid arthritis itself. The mfERG may be an important ophthalmological screening and follow-up management to investigate patients using chloroquine.
PURPOSE: To describe an interesting case with a typical chloroquine bull's eye maculopathy with important results of the electrophysiological tests and verify if any reduction of focal responses, detected in multifocal electroretinogram (mfERG), are congruent with any possible defects detected in the visual field. CASE REPORT: A 59-year-old man took a daily dosage of 250 mg chloroquine for his rheumatoid arthritis (up to a total dose of 540 g). He had the typical chloroquine-induced bull's-eye maculopathy. The electro-oculogram was normal. The mfERG, demonstrated reduced focal responses in the areas corresponding to the scotoma detected in the visual field. CONCLUSIONS: Considering the normality of the electro-oculogram, we can easily conclude that the electro-oculogram is not sensible to detect chloroquinemaculopathy and that reported reductions may occur due to the course of the rheumatoid arthritis itself. The mfERG may be an important ophthalmological screening and follow-up management to investigate patients using chloroquine.
Authors: Michael N Moschos; Marilita M Moschos; Michael Apostolopoulos; John A Mallias; Christos Bouros; George P Theodossiadis Journal: Doc Ophthalmol Date: 2004-01 Impact factor: 2.379
Authors: A S Neubauer; K Samari-Kermani; U Schaller; U Welge-Lübetaen; G Rudolph; T Berninger Journal: Br J Ophthalmol Date: 2003-07 Impact factor: 4.638
Authors: Aline Correa de Carvalho; Martin Schwarz; Givago da Silva Souza; Bruno Duarte Gomes; Alexandre Antônio Marques Rosa; Ana Maria Revoredo da Silva Ventura; José Maria de Souza; Luiz Carlos de Lima Silveira; Jan Kremers Journal: J Ophthalmic Vis Res Date: 2013-07